MEDICUS PHARMA LTD. Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
MEDICUS PHARMA LTD. (MDCX) reported Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest of $3.57 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest · last filed 2026-08-12
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-06-30 was $3.57K.
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$2.86K.
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$225.00.
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was $75.00.
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2025 was -$150.00.
- MEDICUS PHARMA LTD. comprehensive income (loss), net of tax, attributable to noncontrolling interest for fiscal 2024 was $0.00.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.57K 10-Q · filed 2026-08-12 | $713.00 10-Q · filed 2026-08-12 | $488.00 derived: sum of 3 quarters · filed 2026-08-12 | $563.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$2.86K 10-Q · filed 2026-05-14 | -$3.08K derived: sum of 2 quarters · filed 2026-05-14 | -$3.01K derived: sum of 3 quarters · filed 2026-05-14 | -$3.01K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$225.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$150.00 derived: sum of 2 quarters · filed 2026-03-25 | -$150.00 derived: sum of 3 quarters · filed 2026-08-12 | -$150.00 10-K · filed 2026-03-25 |
| 2025-09-30 | $75.00 10-Q · filed 2025-11-14 | $75.00 derived: sum of 2 quarters · filed 2026-08-12 | $75.00 10-Q · filed 2025-11-14 | $75.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |